The Schroder Institutional UK Equity Fund's investment objective is to achieve capital growth through investment in UK equities, although considerable attention will be paid to maintaining a steady growth in income distributions.
Name | % Net Assets |
---|---|
Royal Dutch Shell | 6.0% |
GlaxoSmithKline | 5.7% |
ANGLO AMERICAN | 5.2% |
BG GROUP | 5.0% |
GLAXOSMITHKLINE | 5.0% |
RIO TINTO | 4.6% |
ASTRAZENECA PLC | 4.3% |
UNILEVER | 4.3% |
HSBC HLDGS | 4.1% |
BP | 3.6% |
Key | % Net Assets |
---|---|
Royal Dutch Shell | 6.0% |
GlaxoSmithKline | 5.7% |
ANGLO AMERICAN | 5.2% |
BG GROUP | 5.0% |
Other | 78.1% |
Date | 21-Nov-2024 |
---|---|
NAV | 232.10p |
Currency | GBP |
Change | -0.20p |
% | -0.09% |
YTD change | 10.90p |
YTD % | 4.93% |
Fund Inception | 06/05/1997 |
---|---|
Fund Manager | Jeremy Smith |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.13 |
You are here: research